@article{cc3f4fc7ba934d4385c89b764885e792,
title = "Anti-M{\"u}llerian hormone and risk of ovarian cancer in nine cohorts",
abstract = "Animal and experimental data suggest that anti-M{\"u}llerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable-adjusted conditional logistic regression. AMH concentration was not associated with overall ovarian cancer risk. The multivariable-adjusted OR (95% CI), comparing the highest to the lowest quartile of AMH, was 0.99 (0.59–1.67) (Ptrend: 0.91). The association did not differ by age at blood draw or oral contraceptive use (all Pheterogeneity: ≥0.26). There also was no evidence for heterogeneity of risk for tumors defined by histologic developmental pathway, stage, and grade, and by age at diagnosis and time between blood draw and diagnosis (all Pheterogeneity: ≥0.39). In conclusion, this analysis of mostly late premenopausal women from nine cohorts does not support the hypothesized inverse association between prediagnostic circulating levels of AMH and risk of ovarian cancer.",
keywords = "anti-M{\"u}llerian hormone, epidemiology, ovarian cancer, ovarian function",
author = "Seungyoun Jung and Naomi Allen and Arslan, {Alan A.} and Laura Baglietto and Aurelio Barricarte and Brinton, {Louise A.} and Egleston, {Brian L.} and Falk, {Roni T.} and Fortner, {Ren{\'e}e T.} and Helzlsouer, {Kathy J.} and Yutang Gao and Annika Idahl and Rudolph Kaaks and Vittorio Krogh and Merritt, {Melissa A.} and Eva Lundin and Onland-Moret, {N. Charlotte} and Sabina Rinaldi and Helena Schock and Shu, {Xiao Ou} and Sluss, {Patrick M.} and Staats, {Paul N.} and Carlotta Sacerdote and Travis, {Ruth C.} and Anne Tj{\o}nneland and Antonia Trichopoulou and Tworoger, {Shelley S.} and Kala Visvanathan and Elisabete Weiderpass and Anne Zeleniuch-Jacquotte and Dorgan, {Joanne F.}",
note = "Funding Information: Key words: anti-Mu€llerian hormone, ovarian cancer, epidemiology, ovarian function Abbreviations: AMH: anti-Mu€llerian hormone; BMI: body mass index; CI: confidence interval; OR: odds ratio Additional Supporting Information may be found in the online version of this article. For information on how to submit an application for gaining access to EPIC data and/or biospecimens, please follow the instructions at http://epic.iarc.fr/access/index.php Grant sponsor: U.S. National Institutes of Health (NIH); Grant numbers: R01 CA163018 (to Dr. J.F. Dorgan), UM1 CA186107, R01 CA49449, P01 CA87969 (to the Nurses{\textquoteright} Health Study), UM1 CA17672 (to the Nurses{\textquoteright} Health Study II), R01 CA178949, UM1 CA182934, P30 CA016087, P30 ES000260 (to The NYU Women{\textquoteright}s Health Study); and R37 CA070867, UM1 CA182910 (to The Shanghai Women{\textquoteright}s Health Study); Grant sponsor: Cancer Research UK and the Lloyds TSB Charitable Foundation for the Channel Islands (to the Guernsey Study); Grant sponsor: European Commission (DG-SANCO) and the International Agency for Research on Cancer (for the coordination of the EPIC), Individual national cohorts participating in the EPIC; Grant sponsor: Danish Cancer Society (Denmark); Grant sponsor: Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle G{\'e}n{\'e}rale de l{\textquoteright}Education Nationale, Institut National de la Sant{\'e}et de la Recherche M{\'e}dicale (INSERM) (France); Grant sponsor: German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); Grant sponsor: Hellenic Health Foundation (Greece); Grant sponsor: Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Grant sponsor: Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Grant sponsor: ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); Grant sponsor: Health Research Fund (FIS); Grant number: PI13/00061 (to Granada) and PI13/01162 (to EPIC-Murcia); Grant sponsor: Regional Governments of Andaluc{\'i}a, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC; Grant number: RD06/0020 (Spain); Grant sponsor: Swedish Cancer Society, Swedish Research Council and County Councils of Sk{\aa}ne and V€asterbotten (Sweden); Grant sponsor: Cancer Research UK; Grant number: 14136 (to EPIC-Norfolk) and C570/ A16491 and C8221/A19170 (to EPIC-Oxford); Grant sponsor: Medical Research Council; Grant number: 1000143 (to EPIC-Norfolk) and MR/M012190/1 (to EPIC-Oxford) DOI: 10.1002/ijc.31058 History: Received 28 Apr 2017; Accepted 16 Aug 2017; Online 18 Sep 2017 Correspondence to: Joanne F. Dorgan, University of Maryland School of Medicine, Howard Hall 102E, Baltimore, MD 21201, E-mail: jdorgan@som.umaryland.edu; Tel: 410-706-1602, Fax: 410-706-8013 Publisher Copyright: {\textcopyright} 2017 UICC",
year = "2018",
month = jan,
day = "15",
doi = "10.1002/ijc.31058",
language = "English",
volume = "142",
pages = "262--270",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",
}